Precision Medicine in Oncology

The AJMC® Precision Medicine in Oncology compendium is a comprehensive resource for clinical news and expert insights for molecular profiling of tumors.

Latest News

DNA | Image credit: NHS
Breast Cancer and the Use of Predictive Genomics

June 18th 2025

May 2024 News From Strategic Alliance Partners
May 2024 News From Strategic Alliance Partners

May 20th 2024

New KRYSTAL-1 Data Show 90% Intracranial Disease Control Rate in Patients With KRAS G12C–Mutated NSCLC and Untreated CNS Metastases
New KRYSTAL-1 Data Show 90% Intracranial Disease Control Rate in Patients With KRAS G12C–Mutated NSCLC and Untreated CNS Metastases

August 16th 2023

ASCO 2023 logo
ASCO 2023: Solid Tumors

July 31st 2023

Cathy Eng, MD
FDA Sets Priority Review for Fruquintinib as ASCO Data Confirm Safety Results

June 20th 2023

More News

At Increasing Levels of Sensitivity, NGS-MRD Detects CLL in Bone Marrow
December 14th 2019

At Increasing Levels of Sensitivity, NGS-MRD Detects CLL in Bone Marrow

AJMC Staff
A study presented at the 61st American Society of Hematology (ASH) Annual Meeting and Exposition in Orlando, Florida, discussed the first report of next-generation sequencing (NGS) to test for minimal disease response (MRD) after the combination of ibrutinib plus fludarabine, cyclophosphamide, and rituximab (iFCR) in chronic lymphocytic leukemia (CLL).
Dr Sarah Tasian: NGS Has Revolutionized Treating Children With AML
December 14th 2019

Dr Sarah Tasian: NGS Has Revolutionized Treating Children With AML

The advent of next-generation sequencing (NGS) has meant better care for children with acute myeloid leukemia (AML), a better understanding of rare subtypes of genetic AML, and a better prognosis for these patients, said Sarah Tasian, MD, attending physician in the Division of Oncology at Children’s Hospital of Philadelphia.
Dr John Sweetenham: Issues Persist Among Medicare Beneficiaries for Reimbursement of CAR T-Cell Therapy
December 7th 2019

Dr John Sweetenham: Issues Persist Among Medicare Beneficiaries for Reimbursement of CAR T-Cell Therapy

Reimbursement for CAR-T therapy has progressed to where commercially insured patients obtain coverage regularly, but issues remain for patients with Medicare, said John Sweetenham, MD, professor in the Department of Internal Medicine at UT Southwestern Medical Center and the Associate Director for Clinical Affairs at UTSW’s Harold C. Simmons Comprehensive Cancer Center.
5 Things About Cancer, Genetics, and Germline Screening
December 6th 2019

5 Things About Cancer, Genetics, and Germline Screening

Allison Inserro
Here are 5 things to know about genetic testing in cancer care.
NCCN Releases Updated Breast, Pancreatic, Ovarian Genetic Screening Guidelines
December 6th 2019

NCCN Releases Updated Breast, Pancreatic, Ovarian Genetic Screening Guidelines

Allison Inserro
The update includes a broader, more integrated examination of other high and moderate penetrance genes associated with breast, ovarian, and pancreatic cancer.
Dr John Sweetenham Outlines the Effect of Current Policies on the Implementation of CAR T Therapy
November 29th 2019

Dr John Sweetenham Outlines the Effect of Current Policies on the Implementation of CAR T Therapy

There are a number of policy changes that can drive change within the implementation of chimeric antigen receptor T-cell therapy, but further innovation is warranted to improve access, said John Sweetenham, MD, professor in the Department of Internal Medicine at UT Southwestern Medical Center and the Associate Director for Clinical Affairs at UTSW’s Harold C. Simmons Comprehensive Cancer Center.
Researchers Use Tumor Slices to Understand Microenvironment, Test Therapeutics
November 28th 2019

Researchers Use Tumor Slices to Understand Microenvironment, Test Therapeutics

AJMC Staff
Tumor slices provide a useful platform for studying the tumor microenvironment and evaluating the preclinical efficacy of cancer therapeutics, according to a recent study.
Pancreatic Tumor Classification Could Guide Treatment, Researchers Say
November 23rd 2019

Pancreatic Tumor Classification Could Guide Treatment, Researchers Say

AJMC Staff
Researchers in North Carolina reported discoveries that may lead to further understandings about how pancreatic cancer can become resistant to treatment.
Patients Need More Education Regarding the Purpose of Precision Medicine Trials
November 20th 2019

Patients Need More Education Regarding the Purpose of Precision Medicine Trials

Laura Joszt, MA
Precision medicine may offer new hope to children with high-risk cancer, but only if families and healthcare professionals are fully educated on the benefits and limitations of precision medicine trials, according to a study in Journal of Clinical Oncology.
RNA Sequencing May Be Able to Help Target Therapies for Pediatric Cancers
November 16th 2019

RNA Sequencing May Be Able to Help Target Therapies for Pediatric Cancers

Laura Joszt, MA
Genomic profiling of tumors has become standard in oncology, but tumors in children often do not have actionable DNA aberrations, requiring another way to effectively target treatment for these patients. A study in JAMA Network Open found that RNA sequencing from pediatric and young adult patients may be a feasible approach.
MSK-IMPACT AI Study Yields New Findings to Diagnose Tumor Types of Unknown Origin
November 14th 2019

MSK-IMPACT AI Study Yields New Findings to Diagnose Tumor Types of Unknown Origin

Allison Inserro
A team of researchers led by Memorial Sloan-Kettering Cancer Center Thursday published work describing how they used machine learning, a form of artificial intelligence (AI), to predict tumor type from targeted DNA sequence data to predict tissue of origin, in a finding that may have implications to improve diagnostic and clinical care.
Site Logo
November 10th 2019

The Fast Pace of CAR T-Cell Innovation Caused an Array of Challenges in Treatment

Laura Joszt, MA
The evidence shows that chimeric antigen receptor (CAR) T-cell therapies are effective, but the price tags on these treatments are high and have raised concerns about how many patients will get treated. During a discussion at The American Journal of Managed Care®’s Patient-Centered Oncology Care® meeting, held Friday in Philadelphia, panelists outlined the efficacy of the 2 FDA-approved therapies, Medicare reimbursement for CAR T-cell therapies, and the pace of innovation in healthcare.
Researchers Identify mRNA Biomarker to Predict Response to Chemotherapy
November 9th 2019

Researchers Identify mRNA Biomarker to Predict Response to Chemotherapy

AJMC Staff
A recent study sought to identify an mRNA biomarker that predicts chemosensitivity across multiple solid tumor subtypes, given the significant heterogeneity in response among patients to chemotherapies.
Microsoft Partnering With Cancer Researchers on Genomic Database
November 2nd 2019

Microsoft Partnering With Cancer Researchers on Genomic Database

Allison Inserro
Microsoft is partnering with an independent, nonprofit biomedical research institution on an artificial intelligence, machine learning tool to process the vast amount of data flowing out of genomic research.
Broad Population Genetic Screening Still Faces Implementation Challenges
November 1st 2019

Broad Population Genetic Screening Still Faces Implementation Challenges

Silas Inman
Broad population-based genomic screening has the potential to improve patient care by detecting genetic causes of disease before they occur; however, the economics behind this approach have not fully been validated, according to a session on the clinical and economic utility of whole-genome sequencing at the AMCP Nexus 2019 meeting.
Clinicians Hear More Questions as Patient Awareness of Oncology Genetic Testing Grows
October 24th 2019

Clinicians Hear More Questions as Patient Awareness of Oncology Genetic Testing Grows

Allison Inserro
With increasing awareness of genetic testing and advancements in precision medicine, more patients are seeking counsel from clinicians about what steps they should take if mutations are found. This requires physicians to become more informed, and a recent article discusses the hypothetical case of an Ashkenazi Jewish woman with breast cancer.
CDK4/6 Inhibitors Significantly Improved OS in Women With Advanced Breast Cancer, Studies Show
October 23rd 2019

CDK4/6 Inhibitors Significantly Improved OS in Women With Advanced Breast Cancer, Studies Show

Laura Joszt, MA
Pairing a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor with fulvestrant significantly improved overall survival (OS) for women with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative advanced breast cancer, according to 2 abstracts presented at the European Society of Medical Oncology 2019 Congress.
Researchers Describe Use of 8-Color Flow Cytometry to Determine Level of Response to MM Therapy
October 19th 2019

Researchers Describe Use of 8-Color Flow Cytometry to Determine Level of Response to MM Therapy

AJMC Staff
A recent study described the use of multiparameter flow cytometry to detect minimal residual disease, with an 8-color flow cytometric method with a 105 sensitivity, using monoclonal antibodies in dried formulation.
Educational Resources Needed to Promote MRD Testing for Adults With ALL at Community Practices
October 17th 2019

Educational Resources Needed to Promote MRD Testing for Adults With ALL at Community Practices

Laura Joszt, MA
While measurement of minimal residual disease (MRD) at the end of induction is an important prognostic factor in acute lymphoblastic leukemia (ALL), there is a gap in education among community oncology providers, according to an abstract presented at the Society of Hematologic Oncology 2019 Annual Meeting.
Dr Lee Schwartzberg on the Exclusion of Men From BRCA Screening Recommendations
October 9th 2019

Dr Lee Schwartzberg on the Exclusion of Men From BRCA Screening Recommendations

Lee Schwartzberg, MD, FACP, executive director, West Cancer Center, discusses exclusion of men from the US Preventive Services Task Force's (USPSTF's) updated BRCA screening recommendation update.
Debating the Use of MRD Testing for Treatment Decision Making
October 7th 2019

Debating the Use of MRD Testing for Treatment Decision Making

Laura Joszt, MA
Although minimal residual disease (MRD) is increasingly being used to predict treatment outcomes and as a surrogate marker of progression-free survival, there remains controversy over whether it is ready to be used in treatment decision making.
Nina Chavez on How CAR T, Other Expensive Therapies Create Reimbursement Challenges
October 5th 2019

Nina Chavez on How CAR T, Other Expensive Therapies Create Reimbursement Challenges

Nina Chavez, MBA, FACMPE, chief operating officer, New Mexico Oncology Hematology Consultants, Ltd., explains how expensive therapies like chimeric antigen receptor (CAR) T-cell therapy are creating reimbursement challenges.
Study: All Women With Breast Cancer, Regardless of Family History, Should Undergo Genetic Testing
October 4th 2019

Study: All Women With Breast Cancer, Regardless of Family History, Should Undergo Genetic Testing

Laura Joszt, MA
While current guidelines recommend that only women with breast cancer who have a family history or who meet clinical criteria undergo genetic testing, a new cost-effectiveness analysis suggests that genetic testing should be expanded to all women with breast cancer.
As Relevance of MRD Testing Grows, So Does Access
September 25th 2019

As Relevance of MRD Testing Grows, So Does Access

Laura Joszt, MA
As minimal residual disease (MRD) and other measures to detect cancer burden are increasingly used to predict outcomes and direct future treatment decisions, Amgen has chosen to partner with Adaptive Biotechnologies to use the clonoSEQ product to assess MRD across multiple drug development programs.
Dr Lee Schwartzberg Reacts to USPSTF's BRCA Screening Recommendation Update
September 25th 2019

Dr Lee Schwartzberg Reacts to USPSTF's BRCA Screening Recommendation Update

Lee Schwartzberg, MD, FACP, executive director, West Cancer Center, offers his view on the US Preventive Services Task Force's (USPSTF's) updated recommendation for risk assessment, genetic counseling, and genetic testing for BRCA-related cancer.
Postchemotherapy MRD Status in Colon Cancer May Predict Survival Rates
September 17th 2019

Postchemotherapy MRD Status in Colon Cancer May Predict Survival Rates

Jaime Rosenberg
Researchers found that post-chemotherapy minimal residual disease (MRD) subtypes were associated with a pattern of failure and time to failure.
The Potential of ctDNA as a Prognostic Biomarker in Patients With Colorectal Cancer
September 17th 2019

The Potential of ctDNA as a Prognostic Biomarker in Patients With Colorectal Cancer

Laura Joszt, MA
Oncologists may be able to use circulating tumor DNA (ctDNA) to guide treatment decisions and predict which patients will have disease recurrence, according to 2 studies in JAMA Oncology.
Key Opinion Leaders Underscore Importance of MRD Testing in Multiple Myeloma
September 13th 2019

Key Opinion Leaders Underscore Importance of MRD Testing in Multiple Myeloma

Jaime Rosenberg
The clinical significance of minimal residual disease (MRD) status was recently highlighted in The American Journal of Managed Care®’s Peer Exchange series “A Review of the Treatment for Multiple Myeloma.” During the series, key opinion leaders discussed the clinical implications and significance of MRD testing in patients with multiple myeloma.
All Patients With Metastatic Breast Cancer Should Undergo Germline Testing, Study Finds
September 11th 2019

All Patients With Metastatic Breast Cancer Should Undergo Germline Testing, Study Finds

Laura Joszt, MA
All patients with metastatic breast cancer should undergo genetic testing based on the prevalence of P/LP variants in patients with metastatic breast cancer, which can have therapeutic implications.
Dr John Fox Emphasizes the Importance of Genetic Counseling Before, After Genetic Testing
September 3rd 2019

Dr John Fox Emphasizes the Importance of Genetic Counseling Before, After Genetic Testing

Offering patients genetic counseling before and after they receive genetic testing is crucial for making sure they understand what the results mean, explained John Fox, MD, MHA, vice president of Clinical Transformation at Spectrum Health.
<1
...
567891011121314>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo